CuoripsTSE:4894 -4.13%68 Days Payable is 5,932.21 as of Mar. 2026, which is 51% above its 10-year median of 3,932.63. GuruFocus rates TSE:4894 with a GF Score™ of 68/100 and a GF Value™ of 円28,734.11 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 700 Biotechnology companies, Cuorips ranks better than 82.29% on this metric.
Cuorips's average Accounts Payable for the
six
months ended in Mar. 2026 was 円148.5 Mil. Cuorips's Cost of Goods Sold for the
six
months ended in Mar. 2026 was 円4.6 Mil.
Hence, Cuorips's Days Payable for the
six
months ended in Mar. 2026 was 5,932.21.
The historical rank and industry rank for Cuorips's Days Payable or its related term are showing as below:
TSE:4894'
s Days Payable Range Over the Past 10 Years
Min: 637.15 Med: 3932.63 Max: 343478.19
Current: 637.15
During the past 6 years, Cuorips's highest Days Payable was 343478.19. The lowest was 637.15. And the median was 3932.63.
TSE:4894's Days Payable is ranked better than 82.29% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs TSE:4894: 637.15
Cuorips's Days Payable
increased
from Mar. 2025 (4,481.39) to Mar. 2026 (5,932.21).
It may suggest that Cuoripsdelayed paying its suppliers.
Cuorips Days Payable Related Terms
Cuorips Days Payable Historical Data
* Premium members only.
The historical data trend for Cuorips's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4894 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Cuorips's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuorips Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cuorips's Days Payable distribution charts can be found below:
* The bar in red indicates where Cuorips's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cuorips's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cuorips (TSE:4894) has a Days Payable of 5,932.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cuorips and its competitors. This is 51% above median its historical median of 3,932.63. Over the past decade, Cuorips' Days Payable has ranged from 637.15 to 343,478.19. According to the industry distribution chart, Cuorips ranks #124 out of 700 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Cuorips' Days Payable too high?
Cuorips' current Days Payable of 5,932.21 is 51% above median its 10-year median of 3,932.63. Over the past 10 years, this metric has ranged from a low of 637.15 to a high of 343,478.19. The Biotechnology industry median Days Payable is 113.10. Cuorips' value of 5,932.21 is 5145.1% above this industry median. Based on the distribution chart, Cuorips ranks #124 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cuorips has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cuorips' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cuorips ranks #124 out of 700 companies for Days Payable. This places Cuorips in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Cuorips' value of 5,932.21 is 5145.1% above this benchmark. Historically, Cuorips' own Days Payable has ranged from 637.15 to 343,478.19 over the past decade. While the company's 10-year median is 3,932.63 vs. the industry median of 113.10, Cuorips has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cuorips's current Days Payable of 5,932.21 is 5145.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cuorips and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuorips's current Days Payable is 5,932.21, which is 51% above median its own 10-year median of 3,932.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuorips stock overvalued right now?
Based on GuruFocus' analysis, Cuorips (TSE:4894) is currently considered Possible Value Trap. The stock's GF Value™ is 円28,734.11, compared to a current price of 円4,640.00 — trading 83.9% below its estimated fair value. The current Days Payable is 5,932.21, which is 51% above median its 10-year median of 3,932.63 and 5145.1% above the Biotechnology industry median of 113.10. Cuorips' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cuorips (TSE:4894), the current Days Payable is 5,932.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cuorips (TSE:4894) Overvalued in 2026?
Based on GuruFocus' analysis, Cuorips stock appears to be undervalued.
The current stock price of 円4,640.00 is trading 83.9% below its estimated GF Value™ of 円28,734.11.
GuruFocus considers Cuorips to be Possible Value Trap.
Key valuation signals for TSE:4894:
Days Payable: 5,932.21 (51% above median its 10-year median of 3,932.63)
GF Value™: 円28,734.11 vs. price of 円4,640.00 (83.9% below fair value)
Industry Position: 5145.1% above the Biotechnology median (#124 of 700)
No single metric tells the full story. See the TSE:4894 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
68GF Score
Get the complete analysis for TSE:4894
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4894 has been successfully added to your 
